Richard Brown posted this:
I have several articles in the last 30 days about big phama flush with cash. I got insm at $3.94 and very happy to date. Do you think insm could be a buy out play?
Terry was happy to respond:
ps- Insmed is not a takeover target in 2014,even you should realize that.
I haven't really seen Richardbrown here - he may not know that terry is an insignificant liar.
Richard - In July of 2006 a company named Corrus was purchased by Gilead for 365 Million, plus an undisclosed settlement of a suit that had been filed against Corrus. All told maybe a half billion dollars - give or take.
Corrus was right in the middle of of phase III trials for Cayston - which eventually won FDA approval as a treatment for Cystic Fibrosis.
Arikace has presented phase II results that were far better than Caystons.
In July of 2006, at the time of the merger, Gilead had a market cap of just over 10 Billion dollars.
Gilead now has a market cap of 61 Billion dollars.
Gilead could purchase Insmed for Arikace without batting an eye.
Eventually Cystic Fibrosis patients are expected to use alternative drugs during their current "off" periods.
Gilead could "own" the cystic fibrosis antibiotic market by purchasing Insmed and getting arikace approved.
Insmed has far higher hopes for arikace, and would likely spurn any takeover overtures - the price would have to be many times where it is today.
How this all plays out is anyones guess, but a simple - ps-Insmed is not a takeover target in 2014, even you should know that, should tell you something about that poster.